drugset / Trial / NCT00017693
Recombinant Human IL-4 Receptor Used in Treatment of Asthma
Phase 2
Completed
62 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immunex Corporation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose is to measure the effectiveness of recombinant human interleukin-4 receptor (IL-4R) in treating asthma. Asthma can be caused by the allergic response from breathing in certain irritants. Interleukin 4 (IL-4), which is naturally produced by the body, plays a major role in this allergic response. Doctors feel that IL-4 activity may be stopped by giving IL-4R, a product that binds to IL-4, and thereby decrease the problems of asthma.
Timeline
- Start
- 1998-05
- Primary completion
- 2000-02
- Completion
- 2000-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant human soluble IL-4 receptor | Unknown | 0.75 mg | Inhaled |
| Subject | Recombinant human soluble IL-4 receptor | Unknown | 1.5 mg | Inhaled |
| Subject | Recombinant human soluble IL-4 receptor | Unknown | 3 mg | Inhaled |